ACP
RNAM

Acuta Capital Partners’s Avidity Biosciences RNAM Stock Holding History

Acuta Capital Partners’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-60,000
Closed -$1.48M – 50
2021
Q3 		$1.48M Hold
60,000
– – 0.52% 39
2021
Q2 		$1.48M Sell
60,000
-22,000
-27% -$512K 0.59% 34
2021
Q1 		$1.79M Sell
82,000
-164,200
-67% -$4.02M 0.64% 36
2020
Q4 		$6.28M Buy
246,200
+11,200
+5% +$327K 1.71% 24
2020
Q3 		$6.62M Buy
235,000
+117,500
+100% +$3.4M 1.8% 21
2020
Q2 		$3.32M Buy
+117,500
New +$3.39M 0.96% 35

Other funds holding RNAM

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acuta Capital Partners's RNAM Position: Q4 2021 in Review

Acuta Capital Partners sold out of Avidity Biosciences (RNAM) in Q4 2021, closing a stake of 60,000 shares — an estimated $1.48M sold.

Acuta Capital Partners first reported a position in RNAM in Q2 2020 and held it in 6 quarters. The position peaked at $6.62M in Q3 2020. 107 funds tracked by Wall St. Rank hold RNAM as of Q4 2021.

  • Acuta Capital Partners reported no remaining Avidity Biosciences position as of Q4 2021 after selling out during the quarter.
  • Acuta Capital Partners sold 60,000 Avidity Biosciences shares in Q4 2021, an estimated $1.48M.
  • Acuta Capital Partners first reported a position in Avidity Biosciences in Q2 2020 and held it in 6 quarters.
  • Acuta Capital Partners's Avidity Biosciences position peaked at $6.62M in Q3 2020.
  • 107 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2021.

Based on Acuta Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.